JP2011503207A5 - - Google Patents

Download PDF

Info

Publication number
JP2011503207A5
JP2011503207A5 JP2010534249A JP2010534249A JP2011503207A5 JP 2011503207 A5 JP2011503207 A5 JP 2011503207A5 JP 2010534249 A JP2010534249 A JP 2010534249A JP 2010534249 A JP2010534249 A JP 2010534249A JP 2011503207 A5 JP2011503207 A5 JP 2011503207A5
Authority
JP
Japan
Prior art keywords
promoter
cell
pim
cells
heart
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010534249A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011503207A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/083693 external-priority patent/WO2009065080A1/en
Publication of JP2011503207A publication Critical patent/JP2011503207A/ja
Publication of JP2011503207A5 publication Critical patent/JP2011503207A5/ja
Pending legal-status Critical Current

Links

JP2010534249A 2007-11-16 2008-11-14 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法 Pending JP2011503207A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98875307P 2007-11-16 2007-11-16
US9169808P 2008-08-25 2008-08-25
PCT/US2008/083693 WO2009065080A1 (en) 2007-11-16 2008-11-14 Compositions and method for manipulating pim-1 activity in circulatory system cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014154915A Division JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2011503207A JP2011503207A (ja) 2011-01-27
JP2011503207A5 true JP2011503207A5 (https=) 2012-01-05

Family

ID=40639186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010534249A Pending JP2011503207A (ja) 2007-11-16 2008-11-14 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法
JP2014154915A Expired - Fee Related JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014154915A Expired - Fee Related JP5795670B2 (ja) 2007-11-16 2014-07-30 循環系細胞におけるｐｉｍ−１活性を操作するための組成物および方法

Country Status (5)

Country Link
US (5) US8617534B2 (https=)
EP (1) EP2209889B1 (https=)
JP (2) JP2011503207A (https=)
CA (1) CA2705862C (https=)
WO (1) WO2009065080A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2864100A1 (en) 2012-02-14 2013-08-22 The Regents Of The University Of California Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CA3067558A1 (en) 2017-06-16 2018-12-20 Avery Therapeutics, Inc. Three dimensional tissue compositions and methods of use
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
CN108913655B (zh) * 2018-07-16 2022-07-15 浙江大学 基于多能干细胞技术建立“人源性”心肌肥大模型的方法
US20210386827A1 (en) * 2018-10-15 2021-12-16 Avery Therapeutics, Inc. Cell-free compositions and methods for restoration or enhancement of tissue function
EP4103214B1 (en) 2020-02-13 2026-04-29 Tenaya Therapeutics, Inc. Gene therapy vectors for treating heart disease
WO2022050045A1 (ja) * 2020-09-04 2022-03-10 デクセリアルズ株式会社 導電性積層体及びこれを用いた光学装置、導電性積層体の製造方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217879A (en) 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US20040132190A1 (en) 1995-02-28 2004-07-08 The Regents Of The University Of California Gene therapy for myocardial ischemia
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6007839A (en) 1996-02-16 1999-12-28 The Liposome Company, Inc. Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
US5869037A (en) * 1996-06-26 1999-02-09 Cornell Research Foundation, Inc. Adenoviral-mediated gene transfer to adipocytes
CN1234835A (zh) * 1996-09-05 1999-11-10 加利福尼亚大学董事会 充血性心力衰竭的基因治疗
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
US7198784B2 (en) 1996-10-17 2007-04-03 Oxford Biomedica (Uk) Limited Retroviral vectors
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
IL132463A0 (en) 1997-05-13 2001-03-19 Univ North Carolina Lentivirus - based gene transfer vectors
US6063400A (en) 1997-07-02 2000-05-16 Sdg, Inc. Targeted liposomal constructs for diagnostic and therapeutic uses
CA2304983A1 (en) 1997-09-24 1999-04-01 The Regents Of The University Of California Non-primate lentiviral vectors and packaging systems
ES2373406T3 (es) 1997-12-22 2012-02-03 Oxford Biomedica (Uk) Limited Vectores basados en el virus de la anemia infecciosa equina (vaie).
US6943153B1 (en) 1999-03-15 2005-09-13 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
US6867348B1 (en) * 1999-12-16 2005-03-15 Xenogen Corporation Methods and compositions for screening for angiogenesis modulating compounds
US7122181B2 (en) 2000-12-19 2006-10-17 Research Development Foundation Lentiviral vector-mediated gene transfer and uses thereof
WO2002057413A2 (en) * 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
EP1361896A2 (en) * 2001-01-23 2003-11-19 Boston Scientific Corporation Localized myocardial injection method for treating ischemic myocardium
US20030003582A1 (en) 2001-05-08 2003-01-02 Tranzyme, Inc. Trans-viral vector mediated gene transfer to the retina
US7732199B2 (en) * 2001-07-12 2010-06-08 Geron Corporation Process for making transplantable cardiomyocytes from human embryonic stem cells
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
RU2305708C2 (ru) 2001-10-02 2007-09-10 Энститю Клейтон Де Ля Решерш Рекомбинантный лентивирусный вектор, клетка-хозяин, трансдуцированная лентивирусным вектором, способ ее трансдукции и применение
CA2505251A1 (en) * 2002-11-05 2004-05-27 Brigham And Women's Hospital, Inc. Mesenchymal stem cells and methods of use thereof
CN100567502C (zh) * 2003-04-03 2009-12-09 株式会社康福来 药学制剂
JPWO2004113367A1 (ja) * 2003-06-24 2007-04-12 学校法人慶應義塾 アポトーシス抑制活性を有するペプチド
US7135339B2 (en) 2003-11-20 2006-11-14 University Of Iowa Research Foundation Methods for producing and using in vivo pseudotyped retroviruses using envelope glycoproteins from lymphocytic choriomeningitis virus (LCMV)
JP3903061B2 (ja) 2003-12-24 2007-04-11 株式会社Ｌｔｔバイオファーマ 薬物を含有するナノ粒子およびその製造方法、ならびに当該ナノ粒子からなる非経口投与用製剤
US20050266067A1 (en) 2004-03-02 2005-12-01 Shiladitya Sengupta Nanocell drug delivery system
WO2006014035A1 (en) 2004-08-06 2006-02-09 Biospectrum, Inc. Multiple layered liposome and preparation method thereof
CN101087563A (zh) * 2004-11-08 2007-12-12 约翰霍普金斯大学 活检钳
CA2609937A1 (en) * 2005-05-27 2006-11-30 The Hospital For Sick Children Modulation of the integrin linked kinase signaling pathway to promote cardiac cell proliferation and self-renewal
CN101267805A (zh) 2005-07-27 2008-09-17 普洛体维生物治疗公司 制造脂质体的系统和方法
WO2010135401A2 (en) 2009-05-19 2010-11-25 San Diego State University Foundation Kinase-mediated cytoprotection and enhanced cellular engraftment and persistence

Similar Documents

Publication Publication Date Title
JP2011503207A5 (https=)
ES2401608T3 (es) Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes
Shafei et al. Mesenchymal stem cell therapy: A promising cell‐based therapy for treatment of myocardial infarction
Bhang et al. Angiogenesis in ischemic tissue produced by spheroid grafting of human adipose-derived stromal cells
US20150139952A1 (en) Methods, compositions, cells, and kits for treating ischemic injury
US10174287B2 (en) Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof
JP7854579B1 (ja) 心臓修復のための不死化心筋幹細胞
Ohnishi et al. Prepare cells to repair the heart: mesenchymal stem cells for the treatment of heart failure
Cao et al. Combined hypoxia inducible factor-1α and homogeneous endothelial progenitor cell therapy attenuates shunt flow–induced pulmonary arterial hypertension in rabbits
Zakirova et al. Use of biologically active 3D matrix for extensive skin defect treatment in veterinary practice: Case report
CA2578815A1 (en) Conditioned medium of autologous or allogenic progenitor cells for angiogenesis treatment
Feng et al. Recent concepts for the roles of progenitor/stem cell niche in heart repair
WO2022196714A1 (ja) 塩基性繊維芽細胞増殖因子（ｂＦＧＦ）遺伝子が導入されたペリサイト
Turner et al. Molecular cardiology in translation: gene, cell and chemical-based experimental therapeutics for the failing heart
Lou Human Pluripotent Stem Cells and Patches Enhance the Repairing Efficacy of Infarcted Cardiac Muscle in Mouse Model
Lou Tissue Engineered Cardiac Muscle Patches with Human Pluripotent Stem Cells Enhance the Repairing Efficacy of Infarcted Cardiac Muscle in Mouse Model
Arsenteva et al. STEM CELLS APPLICATION TO ENHANCE THE MYOCARDIAL REGENERATION
Lara-Pezzi et al. Genetic enhancement of cardiac regeneration
CA2897188A1 (en) Cd34 stem cell-related methods and compositions
Papanikolaou et al. Novel Therapies for Heart Failure: The Gene and Cell Methods
Lai et al. Angiomyogenesis for Myocardial repair
Sepúlveda Hypoxia-inducible factor 1 alpha contributes to cardiac healing in mesenchymal stem cells mediated cardiac repair
김미정 Comparison of Viability and Antioxidant Capacity after Freeze-Thawing Between Canine Adipose-Derived Mesenchymal Stem Cells and Heme Oxygenase-1-Overexpressed Cells
Bruckner et al. 160: Human Cord Blood Derived Stem Cells Improve Left Ventricular Function and High Energy Phosphates in a Porcine Model of Myocardial Infarction